BUSINESS● LOW3h ago · Sep 3, 2026, 12:57 PM
Alumis downgraded at Guggenheim after trial setback for SLE candidate
Seeking Alpha Tech · north america
Alumis, a company, was downgraded by Guggenheim following a trial setback for its candidate drug for Systemic Lupus Erythematosus (SLE).
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS11m agoTesla To Launch Self-Driving ‘Cybercab’ In TexasChannels TVBUSINESS14m agoChargePoint CEO says 50% stock surge 'is the beginning of the momentum'CNBCBUSINESS14m agoCiena projects at least 30% revenue growth in fiscal 2027 with $10B+ backlog and 25%-27% operating margin outlookSeeking Alpha TechBUSINESS24m agoRevolut gets conditional US national bank charter approvalSeeking Alpha Tech